Healthcare / Diagnostics & ResearchKuala Lumpur
$0.27
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-953069.00 · quality 45.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
41/100
C
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$40M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-15.1%
↓Gross Margin
64.1%
↑Debt/Equity
0.08
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2021–2025 · 4 años de histórico normalizado
Revenue CAGR
+45.6%
FCF CAGR
—
FCF margin
12.9%
FCF / Net income
-0.43x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $8.0M · net income $-2.4M · FCF $1.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2022 | 2021 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $8.0M | $8.0M | $5.5M | $28.4M | $1.8M |
| Net Income | $-2.4M | $-2.4M | $-4.2M | $7.2M | $-4.3M |
| EBITDA | $-925112.00 | $-925112.00 | $-2.8M | $7.4M | $-3.6M |
| EPS | -0.02 | -0.02 | -0.03 | 0.06 | -0.04 |
| Gross Margin | 64.1% | 64.1% | 62.1% | 48.8% | 68.0% |
| Operating Margin | -9.1% | -9.1% | -82.6% | 21.2% | -243.1% |
| Net Margin | -29.7% | -29.7% | -75.9% | 25.4% | -240.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.08 | 0.08 | 0.09 | 0.04 | 0.09 |
| Current Ratio | 5.53 | 5.53 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.0M | $1.0M | $-953069.00 | $-1.3M | $-6.6M |
| Returns | |||||
| ROE | -15.1% | -15.1% | -23.1% | 19.5% | -23.9% |
| Valuation | |||||
| P/E | — | — | — | 16.21 | — |
| EV/EBITDA | — | — | — | 13.21 | — |
| P/B | 2.31 | 2.31 | 2.65 | 3.15 | 9.18 |
| Growth & Yield | |||||
| Revenue Growth | 45.3% | 45.3% | -80.5% | 1490.1% | — |
| EPS Growth | 43.0% | 43.0% | -152.0% | 246.9% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+17.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.03 → -0.02
Residual
+17.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.